Arcus Biosciences reports Q3 2025 net loss $135M; casdatifan shows 12.2 mo mPFS in late-line kidney cancer

Arcus Biosciences, Inc.

2025-Q3 EPS reported -$2.39 revenue$214,000,000

Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.
Casdatifan pooled analysis (n=121) showed 12.2 months median PFS and 35% ORR at 100mg dose in late-line ccRCC.
Taiho exercised option for casdatifan in Japan/Asia for option payment, milestones, and royalties.
Cash and equivalents $841M; funded through PEAK-1 Phase 3 readout.
Domvanalimab + zimberelimab + chemo showed 26.7 months median OS in EDGE-Gastric study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.